Evidence map›Paper›PMID 24850729›Full record

ArticleJournal of virology2014

Human immunodeficiency virus reverse transcriptase displays dramatically higher fidelity under physiological magnesium conditions in vitro.

Vasudevan Achuthan, Brian J Keith, Bernard A Connolly, Jeffrey J DeStefano

Erratum issuedOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Fidelity of DNA ligase I is sensitive to physiological MgThe Journal of biological chemistry · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Physiological MgBiochemistry · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Vasudevan AchuthanDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, USA.
Brian J KeithInstitute of Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Bernard A ConnollyInstitute of Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Jeffrey J DeStefanoDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, USA jdestefa@umd.edu.
Newcastle University · GBUniversity of Maryland, College Park · US

Funding

MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASER01GM051140 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI DESTEFANO, JEFFREY J · 2000 to 2011
$3.0M
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASER29GM051140 · NIGMS · UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS · PI DESTEFANO, JEFFREY J · 1994 to 1998
–
Biotechnology and Biological Sciences Research Council BB/F00687X/1NIGMS NIH HHS GM051140NIGMS NIH HHS R01 GM051140NIGMS NIH HHS R29 GM051140
6 · The paper itself

Abstract

unlabelledThe fidelity of human immunodeficiency virus (HIV) reverse transcriptase (RT) has been a subject of intensive investigation. The mutation frequencies for the purified enzyme in vitro vary widely but are typically in the 10(-4) range (per nucleotide addition), making the enzyme severalfold less accurate than most polymerases, including other RTs. This has often been cited as a factor in HIV's accelerated generation of genetic diversity. However, cellular experiments suggest that HIV does not have significantly lower fidelity than other retroviruses and shows a mutation frequency in the 10(-5) range. In this report, we reconcile, at least in part, these discrepancies by showing that HIV RT fidelity in vitro is in the same range as cellular results from experiments conducted with physiological (for lymphocytes) concentrations of free Mg(2+) (~0.25 mM) and is comparable to Moloney murine leukemia virus (MuLV) RT fidelity. The physiological conditions produced mutation rates that were 5 to 10 times lower than those obtained under typically employed in vitro conditions optimized for RT activity (5 to 10 mM Mg(2+)). These results were consistent in both commonly used lacZα complementation and steady-state fidelity assays. Interestingly, although HIV RT showed severalfold-lower fidelity under high-Mg(2+) (6 mM) conditions, MuLV RT fidelity was insensitive to Mg(2+). Overall, the results indicate that the fidelity of HIV replication in cells is compatible with findings of experiments carried out in vitro with purified HIV RT, providing more physiological conditions are used. IMPORTANCE: Human immunodeficiency virus rapidly evolves through the generation and subsequent selection of mutants that can circumvent the immune response and escape drug therapy. This process is fueled, in part, by the presumably highly error-prone HIV polymerase reverse transcriptase (RT). Paradoxically, results of studies examining HIV replication in cells indicate an error frequency that is ~10 times lower than the rate for RT in the test tube, which invokes the possibility of factors that make RT more accurate in cells. This study brings the cellular and test tube results in closer agreement by showing that HIV RT is not more error prone than other RTs and, when assayed under physiological magnesium conditions, has a much lower error rate than in typical assays conducted using conditions optimized for enzyme activity.

Indexed as

Reverse TranscriptionCations, DivalentCoenzymesHIV-1HIV Reverse TranscriptaseMagnesiumCations, DivalentCoenzymesHIV Reverse TranscriptaseMagnesium

Identifiers

PMID24850729
PMCPMC4135932
OpenAlexW2111603567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.